Group 1: Company Developments - SenseTime Medical has completed a new round of strategic financing amounting to several hundred million yuan, with investors including Lenovo Capital, Lianchuang Capital, and others, and has initiated Series A financing with subscriptions exceeding 500 million yuan, leading to a post-investment valuation of over 3 billion yuan [2] - SenseTime Medical currently possesses nearly a hundred AI clinical auxiliary diagnostic tools and patient service systems, enabling digital upgrades across major hospitals in Shanghai and nationwide [4] - The company was established as a spin-off from SenseTime Technology, leveraging its SenseCare smart diagnosis platform and foundational algorithm capabilities to develop a "large medical intelligent body development platform" [5] Group 2: Industry Trends - Despite a challenging overall capital market environment, the AI healthcare sector remains active, with companies like Quanjingtong announcing significant financing rounds [3] - The competition in the AI healthcare sector has intensified, with companies vying for data access from hospitals and patients to transform infrequent medical interactions into frequent health consultations [3] - The market for smart healthcare in China is projected to reach 52.86 billion yuan by 2028, with a compound annual growth rate of 67.8% [6] Group 3: Expert Insights - Experts emphasize that AI's role in healthcare should evolve from being a mere tool to becoming a productivity-enhancing force that empowers entire systems and platforms [7] - The potential of AI in healthcare is seen as significant, with the ability to enhance diagnostic accuracy and create personalized treatment plans, thereby rebuilding trust between patients and healthcare providers [6][7]

商汤医疗是一家专注于人工智能技术在医疗领域应用的公司。该公司早在2018年世界人工智能大会上正 式发布了首款医疗AI产品原型SenseCare智慧诊疗平台。这一平台能够辅助医生进行诊断、制定治疗规 划及康复建议，支持对多种器官的异常检测、识别及自动诊断分析，主要服务于放射科、病理科、放疗 科、外科及骨科等重点临床科室。SenseCare提供全面的诊断服务，产品支持涵盖13个身体部位及器官 的诊断，包括心脏、肝脏、肺、胃、肠及宫颈等。此外，还为医疗专业人员及患者提供三维手术规划及 康复建议。该平台可以部署在本地或云端，采用专有的高并发渲染技术，支持来自不同医疗机构多个终 端的并发访问。 证券之星消息，根据天眼查APP于11月16日公布的信息整理，上海商汤善萃医疗科技有限公司Pre-A+轮 融资，融资额数亿人民币，参与投资的机构包括联想创投，联创资本，九弦资本，上海申冉，凯乘资 本。 | 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-11-16 | 联想创投 联创 各本 九弦资本 | 数亿人民币 | Pre-A+轮 | | | 世世史史 | ...

近日，商汤医疗完成数亿元新一轮战略融资，本轮投资方包括联想创投、联创资本、九弦资本、申冉投资等多家知名投资 机构。同时，商汤医疗已同步启动A轮融资，认购金额超5亿元，投后估值超30亿元。 医疗科技公司都在争夺各种数据入口，一方面积极与各大医院合作，抢占医院端入口，另一方面也在抢占患者端入口，希 望把低频的医疗行为变成高频的健康咨询问诊行为。 如果算上正在进行中的A轮融资，今年以来，商汤医疗已经融到第三轮，且基本由产业侧资本主导，这在资本市场并不火 热的当下引发关注。 AI医疗竞赛进入新阶段 第一财经记者注意到，尽管整体资本市场环境尚未完全回暖，但AI医疗赛道的融资仍较为活跃。就在上周，AI医疗公司全 诊通也宣布了1亿元的B轮融资，由创新医疗以及四川佳能达投资有限公司投资。 就在本月，蚂蚁健康宣布原"数字医疗健康事业部"正式升级为"健康事业群"，并将加速推动医疗健康业务成为蚂蚁的战略 支柱板块。有业内人士将蚂蚁健康此次战略升级视为行业内的标志性事件。 商汤医疗由商汤科技拆分智慧医疗板块而成立，其业务基础主要建立在商汤的SenseCare智慧诊疗平台之上，并依托商汤科 技的底层算法能力，构建了"大医智能体开发平台 ...